Atara BiotherapeuticsATRA
Market Cap: $46.9M
About: Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
Employees: 165
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
296% more call options, than puts
Call options by funds: $265K | Put options by funds: $67K
25.16% less ownership
Funds ownership: 83.04% [Q1] → 57.88% (-25.16%) [Q2]
43% less funds holding
Funds holding: 82 [Q1] → 47 (-35) [Q2]
59% less capital invested
Capital invested by funds: $58.8M [Q1] → $24.1M (-$34.7M) [Q2]
74% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 47
97% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 33
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Mizuho Salim Syed 42% 1-year accuracy 8 / 19 met price target | 118%upside $18 | Outperform Upgraded | 16 Aug 2024 |
Canaccord Genuity John Newman 61% 1-year accuracy 11 / 18 met price target | 57%upside $13 | Buy Maintained | 13 Aug 2024 |
Goldman Sachs Tommie Reerink 50% 1-year accuracy 1 / 2 met price target | 33%upside $11 | Sell Maintained | 17 Jul 2024 |
Financial journalist opinion
Based on 3 articles about ATRA published over the past 30 days